ClinicalTrials.gg
Not yet recruitingNCT06272929Updated Feb 22, 2024

Serum Elafin and Vascular Affection in Behcet Disease

An observational study in Behcet Disease and Vascular Affection, sponsored by Assiut University. Not yet recruiting. Open to participants aged 20 Years to 45 Years. Per ClinicalTrials.gov, last updated 2024-02-22.

Sponsored by Assiut University · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Mar 2025, 1 year 8 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Retrospective
Enrollment
90
Ages
20 Years to 45 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 18 studies in Behcet Syndrome by Assiut University — 6 open to participants now, 6 under way, none of them phase 3. Behcet Syndrome · Assiut University.

Planned enrollment
Largest of 14
90 · median 77
Started
2024
with 5 others
Observational
14 of 18
6 open now
Registered
11th of 18
by date

Among the 18 studies in Behcet Syndrome by Assiut University, this one has the largest planned enrollment of the 14 observational ones that give a count, is one of 6 that started in 2024, is one of 14 observational ones, and was the 11th registered.

Behcet Syndrome

136 studies on the registry are indexed under Behcet Syndrome; 42 are open to participants now.

Browse Behcet Syndrome studies →

Open to participants now

6 of the 18 studies in Behcet Syndrome by Assiut University are open now. Recruiting first, the newest first:

All 6 open studies →

Where they have run

Who these studies take

Of the 28 Behcet Syndrome studies recruiting now, 7 (25%) set no upper age limit and 15 (54%) stop at 75 or younger; 7 take children under 18; 7 take healthy volunteers.

This study: 20 Years to 45 Years · all sexes.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies in Behcet Syndrome by Assiut University, or all of them as a file.
02

Study summary

To measure the level of serum elafin in patients with BD. To assess the relation between serum elafin levels and disease activity. To evaluate the vascular complications in BD and determine their relationship with disease activity.

To assess the correlation between serum elafin and vascular affection and their relation with disease activity.

Read the detailed description

Behçet's disease (BD) is a chronic, multisystemic, inflammatory disease characterized by recurrent oral and genital ulcers and multiple systemic involvements. Elafin is a serine protease inhibitor produced mainly by epithelial cells. Its expression is upregulated by proinflammatory cytokines such as IL-1β and TNF-α that are potent stimulants of neutrophil activation, it counteracts the destructive effects of neutrophil elastase .Interestingly, previous reports documented the role of serum elafin in the pathogenesis of BD.In fact, vascular complications may be one of the earliest manifestations leading to the diagnosis of BD. There is no reliable tool to identify vascular wall inflammation in BD, except for detecting intravascular thrombosis with ultrasonography (US). Previous studies investigated arterial vessel wall thickness with US (mostly in carotid arteries) in BD . Venous wall inflammation presents with deep vein thrombosis and superficial thrombophlebitis . It was stated that lower extremity vein wall thickness (VWTs)was increased in BD patients independently of vascular activity and important in the diagnosis . However, studies in the literature evaluated only lower extremity VWTs, whereas the relationship of VWT with disease activity has not been emphasized .

03

Conditions studied

  • Behcet Disease and Vascular Affection

Browse trials for

04

Who can participate

Ages eligible
20 Years to 45 Years
Sexes eligible
All
Sampling method
Non-probability sample

Study population

Patients diagnosed as BD. Age of all participants (20-45) years.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Patients diagnosed as BD. Age of all participants (20-45) years.

Exclusion criteria

Exclusion Criteria:

Age \<20 or >45 years. Other diseases. Cardiovascular diseases (heart failure, myocardial ischemia). Possible related risk factors (e.g. diabetes, dyslipidemia, smoking). chronic conditions (e.g. chronic kidney disease, , autoimmune diseases).

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Observational model
Case-control
Time perspective
Retrospective
Enrollment
90 participants (estimated)
Patient registry
No

Groups and cohorts

  • 45 patients with behcet disease

    Device: doppler ultrasound

  • 45 healthy participants

    Device: doppler ultrasound

Interventions

  • Devicedoppler ultrasound

    doppler US

06

What researchers measure

Primary outcomes

  1. Measuring the level of serum Elafin in patients with BD in comparison to healthy participants.

    Measuring the level of serum Elafin in patients with BD in comparison to healthy participants.

    Time frame: within one year

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Calamia KT, Schirmer M, Melikoglu M. Major vessel involvement in Behcet's disease: an update. Curr Opin Rheumatol. 2011 Jan;23(1):24-31. doi: 10.1097/BOR.0b013e3283410088. PubMed 21124084 ↗
  • Kutlay A, Kose AA. Serum Elafin as a Potential Marker of Disease Activity in Behcet's Disease. Indian J Dermatol. 2023 Jul-Aug;68(4):372-376. doi: 10.4103/ijd.ijd_913_22. PubMed 37822392 ↗
  • Yazici Y, Hatemi G, Bodaghi B, Cheon JH, Suzuki N, Ambrose N, Yazici H. Behcet syndrome. Nat Rev Dis Primers. 2021 Sep 16;7(1):67. doi: 10.1038/s41572-021-00301-1. PubMed 34531393 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Mar 2024; primary completion for Mar 2025, 12 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 16, 2024
First posted
Feb 22, 2024
StartEst.
Mar 1, 2024
Primary completionEst.
Mar 1, 2025
CompletionEst.
Apr 1, 2025
Last update
Feb 22, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 22, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06272929
Lead sponsor
Assiut University
Responsible party
Lobna Amer Araby Ahmed (Assiut, Assiut University) — Principal investigator
First posted
Feb 22, 2024
Start date
Mar 1, 2024 (estimated)
Primary completion
Mar 1, 2025 (estimated)
Completion
Apr 1, 2025 (estimated)
Last update
Feb 22, 2024

Study contacts

Lobna Amer, MD
Contact
lobnaamer20@gmail.com
01019313530

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Feb 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion